Santen Pharmaceutical
Santen Pharmaceutical Co Ltd is a Japanese pharmaceutical company specialized in ophthalmic research, development, and prescription eye care treatments. The company formulates, manufactures, and markets prescription pharmaceuticals, over-the-counter eye drops, and surgical devices for eye conditions including glaucoma, dry eye, and retinal disorders. Revenue is principally generated from the sale of branded ophthalmic medications through prescription channels, hospitals, and pharmacies. Core end markets encompass ophthalmology clinics, eye hospitals, and prescription consumers across Japan, Asia-Pacific, Europe, and the Americas. Santen Pharmaceutical holds the dominant market leadership position in the Japanese prescription ophthalmic market and a prominent international footprint. The company is headquartered in Osaka, Japan, and its shares trade on the Tokyo Stock Exchange.
9 of the funds FundTelligence covers report a position in Santen Pharmaceutical.
- Legal name
- Santen Pharmaceutical Co. Ltd.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 9
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Santen Pharmaceutical
- Nordea Japan Portfolio — Nordea Funds · 0.64 % (full portfolio disclosed, September 2026)
- Danske Invest Japan — Danske Invest · 0.47 % (full portfolio disclosed, August 2026)
- Nordea Global Diversity Engagement Fund — Nordea Funds · 0.41 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.15 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)
- Handelsbanken Utviklede Markeder Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 9 funds holding it.